SEC Info - Harvard Bioscience Inc. - ‘10-K’ for 12/31/23

SEC Info℠

Home

My Interests

Help

Please Sign In

We’re going down soon, to move to a new Data Center today. We’ll be up ASAP. Sorry.

Harvard Bioscience Inc. – ‘10-K’ for 12/31/23 – ‘EX-101.SCH’

On: Thursday, 3/7/24, at 5:00pm ET · For: 12/31/23 · Accession #: 1171843-24-1239 · File #: 1-33957

Previous ‘10-K’: ‘10-K’ on 3/9/23 for 12/31/22 · Latest ‘10-K’: This Filing · 20 References:

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/07/24  Harvard Bioscience Inc.           10-K       12/31/23  113:9.7M                                   Globenewswire Inc./FA

Annual Report — Form 10-K — SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.71M 
 2: EX-21.1     Subsidiaries List                                   HTML     31K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML     30K 
 8: EX-97       Clawback Policy re: Recovery of Erroneously         HTML     38K 
                Awarded Compensation                                             
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     35K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     35K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     31K 
 7: EX-32.2     Certification -- §906 - SOA'02                      HTML     31K 
14: R1          Document And Entity Information                     HTML    100K 
15: R2          Consolidated Balance Sheets                         HTML    137K 
16: R3          Consolidated Balance Sheets (Parentheticals)        HTML     43K 
17: R4          Consolidated Statements of Operations               HTML    102K 
18: R5          Consolidated Statements of Comprehensive Loss       HTML     60K 
19: R6          Consolidated Statements of Comprehensive Loss       HTML     33K 
                (Parentheticals)                                                 
20: R7          Consolidated Statements of Stockholders' Equity     HTML     89K 
21: R8          Consolidated Statements of Cash Flows               HTML    120K 
22: R9          Insider Trading Arrangements                        HTML     49K 
23: R10         Note 1 - Organization                               HTML     34K 
24: R11         Note 2 - Summary of Significant Accounting          HTML    113K 
                Policies                                                         
25: R12         Note 3 - Accumulated Other Comprehensive Loss       HTML     52K 
26: R13         Note 4 - Goodwill and Intangible Assets             HTML     78K 
27: R14         Note 5 - Balance Sheet Information                  HTML     73K 
28: R15         Note 6 - Restructuring and Other Exit Costs         HTML     58K 
29: R16         Note 7 - Employee Benefit Plans                     HTML    111K 
30: R17         Note 8 - Leases                                     HTML     68K 
31: R18         Note 9 - Long-term Debt                             HTML     56K 
32: R19         Note 10 - Derivatives                               HTML     43K 
33: R20         Note 11 - Fair Value Measurements                   HTML     43K 
34: R21         Note 12 - Stock-Based Compensation                  HTML    100K 
35: R22         Note 13 - Revenues                                  HTML     92K 
36: R23         Note 14 - Income Tax                                HTML    130K 
37: R24         Note 15 - Commitments and Contingent Liabilities    HTML     37K 
38: R25         Note 16 - Litigation Settlement                     HTML     35K 
39: R26         Note 17 - Product Line Disposition                  HTML     34K 
40: R27         Note 18 - Government Assistance                     HTML     36K 
41: R28         Significant Accounting Policies (Policies)          HTML    172K 
42: R29         Note 2 - Summary of Significant Accounting          HTML     50K 
                Policies (Tables)                                                
43: R30         Note 3 - Accumulated Other Comprehensive Loss       HTML     51K 
                (Tables)                                                         
44: R31         Note 4 - Goodwill and Intangible Assets (Tables)    HTML     82K 
45: R32         Note 5 - Balance Sheet Information (Tables)         HTML     77K 
46: R33         Note 6 - Restructuring and Other Exit Costs         HTML     55K 
                (Tables)                                                         
47: R34         Note 7 - Employee Benefit Plans (Tables)            HTML    114K 
48: R35         Note 8 - Leases (Tables)                            HTML     72K 
49: R36         Note 9 - Long-term Debt (Tables)                    HTML     49K 
50: R37         Note 10 - Derivatives (Tables)                      HTML     44K 
51: R38         Note 11 - Fair Value Measurements (Tables)          HTML     40K 
52: R39         Note 12 - Stock-Based Compensation (Tables)         HTML     99K 
53: R40         Note 13 - Revenues (Tables)                         HTML     94K 
54: R41         Note 14 - Income Tax (Tables)                       HTML    129K 
55: R42         Note 2 - Summary of Significant Accounting          HTML     77K 
                Policies (Details Textual)                                       
56: R43         Note 2 - Summary of Significant Accounting          HTML     39K 
                Policies - Property, Plant and Equipment (Details)               
57: R44         Note 2 - Summary of Significant Accounting          HTML     64K 
                Policies - Schedule of Basic and Diluted Earnings                
                Per Share (Details)                                              
58: R45         Note 3 - Accumulated Other Comprehensive Loss -     HTML     49K 
                Changes in Each Component of Other Comprehensive                 
                Loss, Net of Tax (Details)                                       
59: R46         Note 4 - Goodwill and Intangible Assets (Details    HTML     35K 
                Textual)                                                         
60: R47         Note 4 - Goodwill and Intangible Assets - Change    HTML     35K 
                in Carrying Amount of Goodwill (Details)                         
61: R48         Note 4 - Goodwill and Intangible Assets -           HTML     52K 
                Intangible Assets (Details)                                      
62: R49         Note 4 - Goodwill and Intangible Assets - Future    HTML     45K 
                Amortization Expense of Intangible Assets                        
                (Details)                                                        
63: R50         Note 5 - Balance Sheet Information (Details         HTML     33K 
                Textual)                                                         
64: R51         Note 5 - Balance Sheet Information - Inventories    HTML     38K 
                (Details)                                                        
65: R52         Note 5 - Balance Sheet Information - Property,      HTML     46K 
                Plant and Equipment (Details)                                    
66: R53         Note 5 - Balance Sheet Information - Other Current  HTML     42K 
                Liabilities (Details)                                            
67: R54         Note 5 - Balance Sheet Information - Long-lived     HTML     35K 
                Assets by Geographic Area (Details)                              
68: R55         Note 6 - Restructuring and Other Exit Costs -       HTML     48K 
                Restructuring and Other Exit Charges (Details)                   
69: R56         Note 7 - Employee Benefit Plans (Details Textual)   HTML     46K 
70: R57         Note 7 - Employee Benefit Plans - Defined Benefit   HTML     41K 
                Pension Expense (Details)                                        
71: R58         Note 7 - Employee Benefit Plans - Change in Fair    HTML     44K 
                Value of Plan Assets (Details)                                   
72: R59         Note 7 - Employee Benefit Plans - Change in         HTML     52K 
                Benefit Obligations (Details)                                    
73: R60         Note 7 - Employee Benefit Plans - Recognized in     HTML     33K 
                Consolidated Balance Sheets (Details)                            
74: R61         Note 7 - Employee Benefit Plans - Weighted Average  HTML     33K 
                Assumptions (Details)                                            
75: R62         Note 7 - Employee Benefit Plans - Fair Value and    HTML     45K 
                Asset Allocations of Pension Benefits (Details)                  
76: R63         Note 7 - Employee Benefit Plans - Fair Value of     HTML     38K 
                Plan Assets By Fair Value Hierarchy (Details)                    
77: R64         Note 8 - Leases - Lease Expense (Details)           HTML     37K 
78: R65         Note 8 - Leases - Supplemental Balance Sheet        HTML     41K 
                Information Related to Operating Leases (Details)                
79: R66         Note 8 - Leases - Supplemental Cash Flow            HTML     33K 
                Information Related to Operating Leases (Details)                
80: R67         Note 8 - Leases - Future Minimum Lease Payments     HTML     48K 
                (Details)                                                        
81: R68         Note 9 - Long-term Debt (Details Textual)           HTML     71K 
82: R69         Note 9 - Long-term Debt - Breakdown of Borrowings   HTML     47K 
                (Details)                                                        
83: R70         Note 9 - Long Term Debt - Debt Maturity (Details)   HTML     37K 
84: R71         Note 10 - Derivatives (Details Textual)             HTML     36K 
85: R72         Note 10 - Derivatives - Derivative Instruments      HTML     34K 
                (Details)                                                        
86: R73         Note 10 - Derivatives - The Effect of Derivatives   HTML     34K 
                Designated as Cash Flow Hedging Instruments                      
                (Details)                                                        
87: R74         Note 11 - Fair Value Measurements - Assets and      HTML     50K 
                Liabilities Measured on a Recurring Basis                        
                (Details)                                                        
88: R75         Note 12 - Stock-Based Compensation (Details         HTML     57K 
                Textual)                                                         
89: R76         Note 12 - Stock-Based Compensation - Stock-based    HTML     39K 
                Compensation Expense (Details)                                   
90: R77         Note 12 - Stock-Based Compensation - Black Scholes  HTML     42K 
                Assumptions (Details)                                            
91: R78         Note 12 - Stock-Based Compensation - Activity of    HTML     71K 
                Restricted Stock and Restricted Stock Units                      
                (Details)                                                        
92: R79         Note 12 - Stock-Based Compensation - Stock-Based    HTML     50K 
                Payment Awards (Details)                                         
93: R80         Note 13 - Revenues (Details Textual)                HTML     31K 
94: R81         Note 13 - Revenues - Disaggregation of Revenue      HTML     41K 
                (Details)                                                        
95: R82         Note 13 - Revenues - Revenue by Geographic          HTML     40K 
                Destination (Details)                                            
96: R83         Note 13 - Revenues - Deferred Revenue (Details)     HTML     38K 
97: R84         Note 13 - Revenues - Allowance for Doubtful         HTML     36K 
                Accounts (Details)                                               
98: R85         Note 13 - Revenues - Warranties (Details)           HTML     35K 
99: R86         Note 14 - Income Tax (Details Textual)              HTML     61K 
100: R87         Note 14 - Income Tax - Income Tax Expense           HTML     48K  
                (Details)                                                        
101: R88         Note 14 - Income Tax - Income Tax Rate              HTML     59K  
                Reconciliation (Details)                                         
102: R89         Note 14 - Income Tax - Pre-tax Income From          HTML     38K  
                Continuing Operations (Details)                                  
103: R90         Note 14 - Income Tax - Deferred Tax Assets and      HTML     74K  
                Liabilities (Details)                                            
104: R91         Note 14 - Income Tax - Unrecognized Tax Benefits    HTML     40K  
                (Details)                                                        
105: R92         Note 15 - Commitments and Contingent Liabilities    HTML     33K  
                (Details Textual)                                                
106: R93         Note 16 - Litigation Settlement (Details Textual)   HTML     53K  
107: R94         Note 17 - Product Line Disposition (Details         HTML     40K  
                Textual)                                                         
108: R95         Note 18 - Government Assistance (Details Textual)   HTML     35K  
110: XML         IDEA XML File -- Filing Summary                      XML    211K  
113: XML         XBRL Instance -- hboi20231231_10k_htm                XML   2.15M  
109: EXCEL       IDEA Workbook of Financial Report Info              XLSX    163K  
10: EX-101.CAL  XBRL Calculations -- hbio-20231231_cal               XML    212K 
11: EX-101.DEF  XBRL Definitions -- hbio-20231231_def                XML   1.55M 
12: EX-101.LAB  XBRL Labels -- hbio-20231231_lab                     XML   1.34M 
13: EX-101.PRE  XBRL Presentations -- hbio-20231231_pre              XML   1.64M 
 9: EX-101.SCH  XBRL Schema -- hbio-20231231                         XSD    249K 
111: JSON        XBRL Instance as JSON Data -- MetaLinks              591±   953K  
112: ZIP         XBRL Zipped Folder -- 0001171843-24-001239-xbrl      Zip    336K

‘EX-101.SCH’ — XBRL Schema — hbio-20231231

This Exhibit is an XBRL File.

<?xml version="1.0" standalone="no" encoding="windows-1252"?>

<xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:hbio="http://www.harvardbioscience.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.harvardbioscience.com/20231231">

<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>

<xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>

<xsd:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>

<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>

<xsd:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>

<xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>

<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>

<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>

<xsd:annotation>

<xsd:appinfo>

<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hbio-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>

<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hbio-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>

<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hbio-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>

<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hbio-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>

<link:roleType id="statement-document-and-entity-information" roleURI="http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information">

<link:definition xmlns="http://www.xbrl.org/2003/linkbase"> 000 - Document - Document And Entity Information </link:definition>